<DOC>
	<DOCNO>NCT02061540</DOCNO>
	<brief_summary>The study open-label study adult primary sclerosing cholangitis evaluate safety , tolerability , effect 14-weeks daily dose LUM001 .</brief_summary>
	<brief_title>Open Label Study Evaluate Safety Efficacy LUM001 Patients With Primary Sclerosing Cholangitis</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<criteria>1 . Male female subject age 1880 year , inclusive . 2 . Diagnosis PSC 3 . If inflammatory bowel disease ( IBD ) present , disease activity ≤ 2 ( normal moderate ) , use physician assessment Mayo ulcerative colitis ( UC ) disease activity score . 4 . Patients receive azathioprine intestinal bowel disease eligible participate study provide IBD exacerbation least 6 month . 5 . Females childbearing potential must negative serum pregnancy test [ β human chorionic gonadotropin ( βhCG ) ] screen negative urine pregnancy test baseline/Day 0 visit . 6 . Sexually active female must postmenopausal , surgically sterile , premenopausal , prepare use effective method ( ≤ 1 % failure rate ) contraception trial . 7 . Ability read understand English order use studyrelated questionnaire text eDiary screen . 8 . Must willing able use eDiary daily minimum 20 week . 9 . Must digitally accept license agreement eDiary software outset study . 10 . Must complete least 10 eDiary Adult ItchRO report ( AM PM ) two consecutive week screen period prior allocation treatment ( maximum possible report = 14 per week ) . 11 . Access phone schedule call study site . 12 . Must agree comply study protocol procedure provide write informed consent . 1 . Small duct PSC ( clinical biochemical histological feature compatible PSC , normal cholangiogram ) . 2 . Presence dominant stricture unless brushing and/or biopsy stricture negative dysplasia malignancy within 6 month screen . 3 . Surgical endoscopic biliary tree intervention treatment clinically significant stricture within 6 month screen . 4 . IBD flare ( Mayo UC disease activity score &gt; 5 include endoscopic evaluation ) within 3 month prior screen . 5 . Secondary cause sclerosing cholangitis ( e.g. , choledocholithiasis , postsurgical biliary stricture , intraarterial chemotherapy , recurrent pancreatitis , IgG4 associate cholangiopathy , AIDS cholangiopathy ) . 6 . AST ALT ≥ 5 x ULN screen . 7 . History presence concomitant significant liver disease assess Investigator . 8 . Medical condition may cause nonhepatic increase ALP ( e.g. , Paget 's disease ) . 9 . Known history human immunodeficiency virus ( HIV ) infection . 10 . The anticipated need surgical procedure within 20 week randomization . 11 . Any female pregnant lactate plan become pregnant within 20 week randomization . 12 . History cancer , except basal squamous cell carcinoma skin , laboratory physical exam diagnostic procedure find suggestive current malignancy . 13 . Family history documented hereditary cancer syndrome . 14 . History alcohol substance abuse within 1 year prior screen . 15 . Receipt investigational drug , biologic , medical device within 30 day prior Screening , 5 halflives study agent , whichever longer . 16 . History noncompliance medical regimen , unreliability , mental instability incompetence could compromise validity inform consent lead noncompliance study protocol . 17 . Any condition abnormality , opinion Investigator Medical Monitor , may compromise safety subject , interfere subject participate completing study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>